BT
The startup develops orally administered small molecules for the treatment of retinal vascular diseases, specifically targeting diabetic retinopathy and age-related macular degeneration. By focusing on de-risked and scientifically validated therapies, the company aims to provide safer and more accessible treatment options for patients suffering from these conditions.
Updated 3 months ago
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops orally administered small molecules for the treatment of retinal vascular diseases, specifically targeting diabetic retinopathy and age-related macular degeneration. By focusing on de-risked and scientifically validated therapies, the company aims to provide safer and more accessible treatment options for patients suffering from these conditions.